Artra Group Corporation
Notice Regarding Capital and Business Alliance with REMED JAPAN Co., Ltd. and Acquisition of Its Shares through Subscription to a Third-Party Allotment (Equity-Method Affiliate)
Subscribed to a third-party allotment in REMED JAPAN and made it an equity-method affiliate by acquiring 35% of voting rights; additionally holds a call option to acquire a further 16% in the future. Through this transaction, aims to strengthen domestic sales channels in Japan and expand A-COMS horizontally. Payment is scheduled for early December 2026, with the second stage targeted around 2029.
Key Figures
- Acquired percentage of voting rights: 35.0%
- Number of shares acquired: 156,154 shares
- Payment timing: early December 2026
- Call option: Additional 16% of voting rights acquirable
- Second-stage target: Raise voting rights to 51%
AI要約
Overview and Purpose of the Alliance
We will subscribe to a third-party allotment in REMED JAPAN and acquire 35% of voting rights, making the company an equity-method affiliate. We have also concluded a basic agreement to expand REMED JAPAN's sales within Japan. As an interim measure, REMED JAPAN will dispatch two directors to our company, and a governance structure will be established whereby significant matters require mutual consent.
Future Developments and Schedule
The first-stage payment is scheduled for early December 2026. We hold the right to exercise a call option to additionally acquire shares equivalent to 16% of voting rights, aiming to raise voting rights to 51% as the second stage. The exercise timing will be a specified period after the fiscal year ending December 2028 closing, and valuation will be calculated using an EBITDA multiple method.
Artra Group Corporation
Company overview · Stock price · Financial data · All IR